Yiting Qiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yiting Qiao has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Jianxiang Chen
School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, PR China.
10 shared publications Jiacheng Huang
Division of Hepatobiliary and Pancreatic Surgery Department of Surgery The First Affiliated Hospital, Zhejiang University School of Medicine NHC Key Laboratory of Combined Multi‐organ Transplantation Key Laboratory of Organ Transplantation Key Laboratory of the Diagnosis and Treatment of Organ Transplantation Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer Chinese Academy of Medical Science (2019RU019) Hangzhou 310003 China
6 shared publicationsMenglan Wang
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Department of Hepatology the Affiliated Hospital of Hangzhou Normal University Hangzhou 311121 China
6 shared publicationsMengqing Sun
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Department of Hepatology the Affiliated Hospital of Hangzhou Normal University Hangzhou 311121 China
6 shared publicationsHeng Dong
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Department of Hepatology the Affiliated Hospital of Hangzhou Normal University Hangzhou 311121 China
5 shared publicationsLin Zhou
Division of Hepatobiliary and Pancreatic Surgery Department of Surgery The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
4 shared publications
Latest Publications
- Open Access
- 25 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (47) , e75801
PGK1 Suppresses CD8 + T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma
Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis and few effective treatments. The highly immunosuppressive tumor microenvironment and multifaceted immune escape mechanisms in HCC profoundly restrict the clinical efficacy of immune checkpoint inhibitors. Phosphoglycerate kinase 1 (PGK1) is established as an oncogenic driver in malignant tumor progression. However, its role in modulating tumor immunity remains elusive. This study found that HCC cell‐intrinsic PGK1 contributed to tumor progression through inhibiting CD8 + T cell‐mediated antitumor immunity. Then, in vivo and in vitro results demonstrated that tumor‐associated macrophages (TAMs) function as critical mediators in PGK1‐driven immunosuppression. Furthermore, PGK1 promoted the recruitment and M2 polarization of TAMs through upregulation of C‐C motif chemokine ligand 2 (CCL2) expression. Blockade of CCL2 significantly attenuated PGK1‐induced infiltration of C‐C motif chemokine receptor 2 (CCR2) + TAMs and inhibited M2 polarization, while reversing the impaired infiltration and function of CD8 + T cells. This work further demonstrated that PGK1 enhanced CCL2 secretion through activating the AKT/GSK3β/β‐catenin pathway in HCC cells. In vivo experiments revealed that the combination of PGK1 inhibitor and immunotherapy elicited potent antitumor efficacy. Taken together, this study highlighted PGK1 as a pivotal regulator of tumor immunobiology and provided novel insights into combination immunotherapy for HCC.
- 25 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (47) , e75801
Open AccessPGK1 Suppresses CD8 + T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma
Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis and few effective treatments. The highly immunosuppressive tumor microenvironment and multifaceted immune escape mechanisms in HCC profoundly restrict the clinical efficacy of immune checkpoint inhibitors. Phosphoglycerate kinase 1 (PGK1) is established as an oncogenic driver in malignant tumor progression. However, its role in modulating tumor immunity remains elusive. This study found that HCC cell‐intrinsic PGK1 contributed to tumor progression through inhibiting CD8 + T cell‐mediated antitumor immunity. Then, in vivo and in vitro results demonstrated that tumor‐associated macrophages (TAMs) function as critical mediators in PGK1‐driven immunosuppression. Furthermore, PGK1 promoted the recruitment and M2 polarization of TAMs through upregulation of C‐C motif chemokine ligand 2 (CCL2) expression. Blockade of CCL2 significantly attenuated PGK1‐induced infiltration of C‐C motif chemokine receptor 2 (CCR2) + TAMs and inhibited M2 polarization, while reversing the impaired infiltration and function of CD8 + T cells. This work further demonstrated that PGK1 enhanced CCL2 secretion through activating the AKT/GSK3β/β‐catenin pathway in HCC cells. In vivo experiments revealed that the combination of PGK1 inhibitor and immunotherapy elicited potent antitumor efficacy. Taken together, this study highlighted PGK1 as a pivotal regulator of tumor immunobiology and provided novel insights into combination immunotherapy for HCC.
- Open Access
- 12 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (11) , e11887
Elemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis
Immune checkpoint inhibitors, particularly PD‐1 inhibitors, constitute the cornerstone of first‐line treatment for hepatocellular carcinoma (HCC). However, suboptimal overall response rates persist alongside dual challenges: immune‐related toxicities and immunosuppressive tumor microenvironment. Combination therapies represent a pivotal strategy to overcome these limitations. In recent years, traditional Chinese medicine has gained significant attention. Elemene, a small‐molecule compound derived from Curcuma wenyujin , has garnered attention for its immunomodulatory potential and demonstrates clinical efficacy in combination therapies. Nevertheless, its synergistic mechanisms with immunotherapy remain incompletely characterized. This study demonstrates for the first time that elemene modulates the miR‐130a‐5p/SPP/MHC‐I axis, resulting in an enhanced diversity and abundance of antigen/MHC‐I complexes on the surface of HCC cells. This mechanism promotes the recognition and elimination of HCC cells by cytotoxic T lymphocytes, thereby augmenting the antitumor immune efficacy of PD‐1. Moreover, the functional significance of the miR‐130a‐5p/SPP/MHC‐I axis in modulating the tumor immune microenvironment is systematically validated through in vitro and in vivo HCC models, as well as in clinical patient specimens. These findings underscore the potential of combining elemene with anti‐PD‐1 therapy as a safe and effective treatment strategy for HCC, offering significant translational promise for improving patient outcomes.
- 12 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (11) , e11887
Open AccessElemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis
Immune checkpoint inhibitors, particularly PD‐1 inhibitors, constitute the cornerstone of first‐line treatment for hepatocellular carcinoma (HCC). However, suboptimal overall response rates persist alongside dual challenges: immune‐related toxicities and immunosuppressive tumor microenvironment. Combination therapies represent a pivotal strategy to overcome these limitations. In recent years, traditional Chinese medicine has gained significant attention. Elemene, a small‐molecule compound derived from Curcuma wenyujin , has garnered attention for its immunomodulatory potential and demonstrates clinical efficacy in combination therapies. Nevertheless, its synergistic mechanisms with immunotherapy remain incompletely characterized. This study demonstrates for the first time that elemene modulates the miR‐130a‐5p/SPP/MHC‐I axis, resulting in an enhanced diversity and abundance of antigen/MHC‐I complexes on the surface of HCC cells. This mechanism promotes the recognition and elimination of HCC cells by cytotoxic T lymphocytes, thereby augmenting the antitumor immune efficacy of PD‐1. Moreover, the functional significance of the miR‐130a‐5p/SPP/MHC‐I axis in modulating the tumor immune microenvironment is systematically validated through in vitro and in vivo HCC models, as well as in clinical patient specimens. These findings underscore the potential of combining elemene with anti‐PD‐1 therapy as a safe and effective treatment strategy for HCC, offering significant translational promise for improving patient outcomes.
- Top Cited PapersOpen Access
- 24 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 733
Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy
The highly fibrotic extracellular matrix (ECM) constitutes a major barrier that restricts the penetration and delivery efficiency of anticancer drugs, part
- 24 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 733
Top Cited PapersOpen AccessCollagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy
The highly fibrotic extracellular matrix (ECM) constitutes a major barrier that restricts the penetration and delivery efficiency of anticancer drugs, part
- Open Access
- 3 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 803-819
Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma
- 3 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 803-819
Open AccessRedistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma
- Open Access
- 27 July 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (12) , 5418-5434
Development of a bacteria-nanosapper for the active delivery of ZIF-8 particles containing therapeutic genes for cancer immune therapy
- 27 July 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (12) , 5418-5434
Open AccessDevelopment of a bacteria-nanosapper for the active delivery of ZIF-8 particles containing therapeutic genes for cancer immune therapy
- Open Access
- 7 January 2024
- Published by Taylor & Francis in Bioengineered
- Vol. 15 (1) , 2296775
Establishment and characterization of a highly metastatic hepatocellular carcinoma cell line
The prevalence of alcohol-related hepatocellular carcinoma (HCC) has been increasing during the last decade. Cancer research requires cell lines suitable for both in vitro and in vivo assays. However, there is a lack of cell lines with a high in vivo metastatic capacity for this HCC subtype. Herein, a new HCC cell line was established, named HCC-ZJ, using cells from a patient diagnosed with alcohol-related HCC. The karyotype of HCC-ZJ was 46, XY, del (p11.2). Whole-exome sequencing identified several genetic variations in HCC-Z that occur frequently in alcohol-associated HCC, such as mutations in TERT, CTNNB1, ARID1A, CDKN2A, SMARCA2, and HGF. Cell counting kit-8 assays, colony formation assays, and Transwell assays were performed to evaluate the proliferation, migration, and sensitivity to sorafenib and lenvatinib of HCC-Z in vitro. HCC-ZJ showed a robust proliferation rate, a weak foci-forming ability, a strong migration capacity, and a moderate invasion tendency in vitro. Finally, the tumorigenicity and metastatic capacity of HCC-Z were evaluated using a subcutaneous xenograft model, an orthotopic xenograft model, and a tail-veil injection model. HCCZJ exhibited strong tumorigenicity in the subcutaneous xenograft and orthotopic tumor models. Moreover, HCC-ZJ spontaneously formed pulmonary metastases in the orthotopic tumor model. In summary, a new HCC cell line derived from a patient with alcohol-related HCC was established, which showed a high metastatic capacity and could be applied for in vitro and in vivo experiments during pre-clinical research.Highlights• An alcohol-related HCC cell line, HCC-ZJ, was established• HCC-ZJ was applicable for in vitro functional experiment and gene editing• HCC-ZJ was applicable for in vivo tumor growth and spontaneous metastasis models.
- 7 January 2024
- Published by Taylor & Francis in Bioengineered
- Vol. 15 (1) , 2296775
Open AccessEstablishment and characterization of a highly metastatic hepatocellular carcinoma cell line
The prevalence of alcohol-related hepatocellular carcinoma (HCC) has been increasing during the last decade. Cancer research requires cell lines suitable for both in vitro and in vivo assays. However, there is a lack of cell lines with a high in vivo metastatic capacity for this HCC subtype. Herein, a new HCC cell line was established, named HCC-ZJ, using cells from a patient diagnosed with alcohol-related HCC. The karyotype of HCC-ZJ was 46, XY, del (p11.2). Whole-exome sequencing identified several genetic variations in HCC-Z that occur frequently in alcohol-associated HCC, such as mutations in TERT, CTNNB1, ARID1A, CDKN2A, SMARCA2, and HGF. Cell counting kit-8 assays, colony formation assays, and Transwell assays were performed to evaluate the proliferation, migration, and sensitivity to sorafenib and lenvatinib of HCC-Z in vitro. HCC-ZJ showed a robust proliferation rate, a weak foci-forming ability, a strong migration capacity, and a moderate invasion tendency in vitro. Finally, the tumorigenicity and metastatic capacity of HCC-Z were evaluated using a subcutaneous xenograft model, an orthotopic xenograft model, and a tail-veil injection model. HCCZJ exhibited strong tumorigenicity in the subcutaneous xenograft and orthotopic tumor models. Moreover, HCC-ZJ spontaneously formed pulmonary metastases in the orthotopic tumor model. In summary, a new HCC cell line derived from a patient with alcohol-related HCC was established, which showed a high metastatic capacity and could be applied for in vitro and in vivo experiments during pre-clinical research.Highlights• An alcohol-related HCC cell line, HCC-ZJ, was established• HCC-ZJ was applicable for in vitro functional experiment and gene editing• HCC-ZJ was applicable for in vivo tumor growth and spontaneous metastasis models.
- Open Access
- 13 November 2023
- Published by Springer Nature in Oncogenesis
- Vol. 12 (1) , 1-10
Kinesin family member 18B activates mTORC1 signaling via actin gamma 1 to promote the recurrence of human hepatocellular carcinoma
The mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway is frequently reported to be hyperactivated in hepatocellular carcinoma (HCC) and contributes to HCC recurrence. However, the underlying regulatory mechanisms of mTORC1 signaling in HCC are not fully understood. In the present study, we found that the expression of kinesin family member 18B (KIF18B) was positively correlated with mTORC1 signaling in HCC, and the upregulation of KIF18B and p-mTOR was associated with a poor prognosis and HCC recurrence. Utilizing in vitro and in vivo assays, we showed that KIF18B promoted HCC cell proliferation and migration through activating mTORC1 signaling. Mechanistically, we identified Actin gamma 1 (γ-Actin) as a binding partner of KIF18B. KIF18B and γ-Actin synergistically modulated lysosome positioning, promoted mTORC1 translocation to lysosome membrane, and prohibited p70 S6K from entering lysosomes for degradation, which finally led to the enhancement of mTORC1 signaling transduction. Moreover, we found that KIF18B was a direct target of Forkhead box M1, which explains the potential mechanism of KIF18B overexpression in HCC. Our study highlights the potential of KIF18B as a therapeutic target for the treatment of HCC.
- 13 November 2023
- Published by Springer Nature in Oncogenesis
- Vol. 12 (1) , 1-10
Open AccessKinesin family member 18B activates mTORC1 signaling via actin gamma 1 to promote the recurrence of human hepatocellular carcinoma
The mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway is frequently reported to be hyperactivated in hepatocellular carcinoma (HCC) and contributes to HCC recurrence. However, the underlying regulatory mechanisms of mTORC1 signaling in HCC are not fully understood. In the present study, we found that the expression of kinesin family member 18B (KIF18B) was positively correlated with mTORC1 signaling in HCC, and the upregulation of KIF18B and p-mTOR was associated with a poor prognosis and HCC recurrence. Utilizing in vitro and in vivo assays, we showed that KIF18B promoted HCC cell proliferation and migration through activating mTORC1 signaling. Mechanistically, we identified Actin gamma 1 (γ-Actin) as a binding partner of KIF18B. KIF18B and γ-Actin synergistically modulated lysosome positioning, promoted mTORC1 translocation to lysosome membrane, and prohibited p70 S6K from entering lysosomes for degradation, which finally led to the enhancement of mTORC1 signaling transduction. Moreover, we found that KIF18B was a direct target of Forkhead box M1, which explains the potential mechanism of KIF18B overexpression in HCC. Our study highlights the potential of KIF18B as a therapeutic target for the treatment of HCC.
- Open Access
- 7 October 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 980111
Bacteria-mediated cancer therapy: A versatile bio-sapper with translational potential
Bacteria are important symbionts for humans, which sustain substantial influences on our health. Interestingly, some bastrains have been identified to have therapeutic applications, notably for antitumor activity. Thereby, oncologists have developed various therapeutic models and investigated the potential antitumor mechanisms for bacteria-mediated cancer therapy (BCT). Even though BCT has a long history and exhibits remarkable therapeutic efficacy in pre-clinical animal models, its clinical translation still lags and requires further breakthroughs. This review aims to focus on the established strains of therapeutic bacteria and their antitumor mechanisms, including the stimulation of host immune responses, direct cytotoxicity, the interference on cellular signal transduction, extracellular matrix remodeling, neoangiogenesis, and metabolism, as well as vehicles for drug delivery and gene therapy. Moreover, a brief discussion is proposed regarding the important future directions for this fantastic research field of BCT at the end of this review.
- 7 October 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 980111
Open AccessBacteria-mediated cancer therapy: A versatile bio-sapper with translational potential
Bacteria are important symbionts for humans, which sustain substantial influences on our health. Interestingly, some bastrains have been identified to have therapeutic applications, notably for antitumor activity. Thereby, oncologists have developed various therapeutic models and investigated the potential antitumor mechanisms for bacteria-mediated cancer therapy (BCT). Even though BCT has a long history and exhibits remarkable therapeutic efficacy in pre-clinical animal models, its clinical translation still lags and requires further breakthroughs. This review aims to focus on the established strains of therapeutic bacteria and their antitumor mechanisms, including the stimulation of host immune responses, direct cytotoxicity, the interference on cellular signal transduction, extracellular matrix remodeling, neoangiogenesis, and metabolism, as well as vehicles for drug delivery and gene therapy. Moreover, a brief discussion is proposed regarding the important future directions for this fantastic research field of BCT at the end of this review.
- Open Access
- 24 January 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 836223
Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe
Tumorigenesis is frequently accompanied by chronic inflammation, and the tumor microenvironment (TME) can be considered an ecosystem that consists of tumor cells, endotheliocytes, fibroblasts, immune cells and acellular components such as extracellular matrix. For tumor cells, their survival advantages are dependent on both genetic and epigenetic alterations, while other cells mainly present epigenetic modifications. Macrophages are the most plastic type of immune cells and undergo diverse epigenetic alterations in the TME. Some of these epigenetic modifications mitigate against cancer progression, and others accelerate this process. Due to the complex roles of macrophages in the TME, it is urgent to understand their epigenetic modifications associated with the TME. Here, we mainly summarize recent findings on TME-associated epigenetic alterations of tumor-associated macrophages (TAMs), including DNA methylation, posttranslational modifications of histone proteins, chromatin remodeling, and noncoding RNA-mediated epigenetic regulation. At the end of this review, we also discuss the translational potential of these epigenetic modifications for developing novel cancer therapies targeting TAMs.
- 24 January 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 836223
Open AccessEpigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe
Tumorigenesis is frequently accompanied by chronic inflammation, and the tumor microenvironment (TME) can be considered an ecosystem that consists of tumor cells, endotheliocytes, fibroblasts, immune cells and acellular components such as extracellular matrix. For tumor cells, their survival advantages are dependent on both genetic and epigenetic alterations, while other cells mainly present epigenetic modifications. Macrophages are the most plastic type of immune cells and undergo diverse epigenetic alterations in the TME. Some of these epigenetic modifications mitigate against cancer progression, and others accelerate this process. Due to the complex roles of macrophages in the TME, it is urgent to understand their epigenetic modifications associated with the TME. Here, we mainly summarize recent findings on TME-associated epigenetic alterations of tumor-associated macrophages (TAMs), including DNA methylation, posttranslational modifications of histone proteins, chromatin remodeling, and noncoding RNA-mediated epigenetic regulation. At the end of this review, we also discuss the translational potential of these epigenetic modifications for developing novel cancer therapies targeting TAMs.
- Open Access
- 28 September 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
Background: Tumor-infiltrating immune cells are important components of tumor microenvironment (TME), and their composition reflects the confrontation between host immune system and tumor cells. However, the relationship between the composition of infiltrating immune cells, prognosis, and the applicability of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma (HCC) needs systematic examination.Methods: Cell-Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) was applied to evaluate the infiltration of immune cells based on The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) cohort. Diagnostic and prognostic models were constructed based on immune cells, and the models were validated by two external cohorts. The relationship between immune cells and PD-L1 was evaluated by Spearman correlation, and the finding was validated in our in-house HCC sample.Result: Patients in TCGA LIHC cohort were classified into six subtypes with different prognosis based on the proportion of tumor-infiltrating immune cells simulated via CIBERSORT. Among 22 types of immune cells, intratumoral PD-L1 mRNA level exhibited linear relationship with the fraction of five types of immune cells (M1 macrophages, plasma cells, CD8+ T cells, resting mast cells, and regulatory T cells), and M1 macrophages showed the strongest relevance (R = 0.26, p < 0.001). Immunohistochemistry of our in-house HCC specimens verified this conclusion. Moreover, intratumoral mRNA levels of M1 macrophage-associated cytokines were positively correlated with PD-L1 level.Conclusions: Our study demonstrated that the prognosis of HCC patients was associated with the pattern of infiltrating immune cells in TME, and macrophage-associated cytokines might be a potential non-invasive marker for predicting the PD-L1 level for HCC patients.
- 28 September 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessThe Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
Background: Tumor-infiltrating immune cells are important components of tumor microenvironment (TME), and their composition reflects the confrontation between host immune system and tumor cells. However, the relationship between the composition of infiltrating immune cells, prognosis, and the applicability of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma (HCC) needs systematic examination.Methods: Cell-Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) was applied to evaluate the infiltration of immune cells based on The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) cohort. Diagnostic and prognostic models were constructed based on immune cells, and the models were validated by two external cohorts. The relationship between immune cells and PD-L1 was evaluated by Spearman correlation, and the finding was validated in our in-house HCC sample.Result: Patients in TCGA LIHC cohort were classified into six subtypes with different prognosis based on the proportion of tumor-infiltrating immune cells simulated via CIBERSORT. Among 22 types of immune cells, intratumoral PD-L1 mRNA level exhibited linear relationship with the fraction of five types of immune cells (M1 macrophages, plasma cells, CD8+ T cells, resting mast cells, and regulatory T cells), and M1 macrophages showed the strongest relevance (R = 0.26, p < 0.001). Immunohistochemistry of our in-house HCC specimens verified this conclusion. Moreover, intratumoral mRNA levels of M1 macrophage-associated cytokines were positively correlated with PD-L1 level.Conclusions: Our study demonstrated that the prognosis of HCC patients was associated with the pattern of infiltrating immune cells in TME, and macrophage-associated cytokines might be a potential non-invasive marker for predicting the PD-L1 level for HCC patients.